NASDAQ · RYTM
Healthcare · Biotechnology
$102.20
Up+$1.14 (+1.13%)
Updated Sep 11, 2026, 4:58 AM
SID Score
4.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RYTM closed at $102.20 after 20 trading sessions, down 11.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $99.88 | $102.89 | $99.88 | $102.20 | 422.89K |
| Sep 9, 2026 | $100.23 | $101.77 | $99.8325 | $101.06 | 482.25K |
| Sep 8, 2026 | $100.58 | $103.31 | $99.41 | $101.80 | 513.05K |
| Sep 4, 2026 | $103.53 | $105.71 | $101.25 | $102.74 | 466.91K |
| Sep 3, 2026 | $106.08 | $106.08 | $103.9025 | $104.89 | 269.77K |
| Sep 2, 2026 | $105.50 | $108.57 | $103.95 | $105.42 | 455.59K |
| Sep 1, 2026 | $105.79 | $108.43 | $104.09 | $104.74 | 332.05K |
| Aug 31, 2026 | $106.01 | $108.845 | $103.98 | $106.13 | 775.19K |
| Aug 28, 2026 | $110.21 | $114.75 | $107.09 | $107.17 | 441.21K |
| Aug 27, 2026 | $111.21 | $113.97 | $110.0301 | $112.53 | 311.07K |
| Aug 26, 2026 | $113.21 | $114.75 | $111.35 | $111.87 | 358.96K |
| Aug 25, 2026 | $112.73 | $114.07 | $111.79 | $113.35 | 352.46K |
| Aug 24, 2026 | $112.29 | $113.60 | $109.89 | $111.44 | 400.56K |
| Aug 21, 2026 | $109.38 | $112.59 | $106.58 | $110.00 | 523.14K |
| Aug 20, 2026 | $114.51 | $114.605 | $108.7267 | $108.92 | 568.58K |
| Aug 19, 2026 | $118.31 | $118.31 | $115.26 | $115.73 | 669.9K |
| Aug 18, 2026 | $115.25 | $117.16 | $114.325 | $115.25 | 447.06K |
| Aug 17, 2026 | $115.40 | $117.18 | $114.44 | $115.44 | 412.05K |
| Aug 14, 2026 | $115.22 | $117.3337 | $113.66 | $115.48 | 334.88K |
| Aug 13, 2026 | $118.18 | $119.75 | $114.00 | $116.02 | 759.78K |
The latest Smart Investors Daily articles mentioning RYTM.
RYTM research
Company profile and research snapshot.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Deutsche Bank | Hold | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | Citizens | Market Outperform | — |
| Aug 5, 2026 | RBC Capital | Outperform | — |
| Aug 5, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 2, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on an annualized basis producing an average annual return of 51.66%. Currently, Rhythm Pharmaceuticals has a market
Benzinga · Aug 31, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on an annualized basis producing an average annual return of 52.06%. Currently, Rhythm Pharmaceuticals has a market
Benzinga · Aug 28, 2026
Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.
Yahoo · Aug 26, 2026
Rhythm Pharmaceuticals has delivered very strong long-term share price gains, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. The stock is up about 7x over 5 years, which puts extra focus on whether recent gains already reflect much of the company story. Approval of IMCIVREE for acquired hypothalamic obesity in Japan may support expectations for future revenue growth, while execution risk around pricing, uptake...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RYTM.
